Home / Business and Economy / AbbVie, Lilly: Top Pharma Buys for New Year
AbbVie, Lilly: Top Pharma Buys for New Year
14 Dec
Summary
- AbbVie boasts 54 consecutive years of dividend increases, earning Dividend King status.
- AbbVie's Skyrizi projected to become world's second-best selling drug by 2030.
- Eli Lilly reported a 54% year-over-year revenue increase in its latest quarter.
As the new year approaches, the healthcare sector is under scrutiny for its potential to outperform other equities. While the industry's overall trajectory remains uncertain, several key healthcare stocks are emerging as compelling investment opportunities for 2026.
AbbVie stands out as a strong contender, particularly for income-focused investors. This pharmaceutical giant is a distinguished Dividend King, marked by an impressive 54-year streak of consecutive dividend increases. Its robust business model supports consistent revenue and earnings, driven by successful products like Skyrizi and Rinvoq. Skyrizi, in particular, is forecasted to become the world's second-highest-grossing drug by 2030, surpassing even AbbVie's former flagship, Humira.
Complementing AbbVie's stability, Eli Lilly showcases exceptional growth. The company recently posted a remarkable 54% year-over-year increase in third-quarter revenue, signaling significant momentum. These pharmaceutical powerhouses, alongside others like Intuitive Surgical, represent strong prospects for investors seeking both consistent returns and significant growth potential in the evolving healthcare landscape.
